Pion has pioneered reliable methods for predicting the absorption potential of finished dosage products prior to clinical trials. New testing technology allows Pion to combine traditional dissolution testing with repeatable methods for assessing the absorption potential of APIs, API/ingredient combinations, or finished dosage products. As a result, Pion can more reliably and realistically test and model IVIVC (in vitro-in vivo correlation). Pion’s approach allows potential problems with the permeability and absorption potential of a promising compound to be identified far earlier in the development process. In addition, Pion can accurately predict the absorption potential and bioequivalence of various finished dosage products earlier in development. This capability facilitates better decision-making and resource allocation by pharmaceutical developers.